FDA’s second approval of an amyloid imaging agent, GE Healthcare's Vizamyl, reinforced the viability of the regulatory path for radiopharmaceutical imaging drugs that target beta amyloid even as the agency continues to question the usefulness of such scans in clinical practice.
The development of PET amyloid imaging agents “rests on the notion that the detection of β amyloid in brain scans can provide clinically useful information,” FDA Division of Medical Imaging...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?